作者: Véronique Tack , Marjolijn J.L. Ligtenberg , Lien Tembuyser , Nicola Normanno , Sara Vander Borght
DOI: 10.1634/THEONCOLOGIST.2014-0382
关键词:
摘要: BACKGROUND: Regulations for the selection of patients with metastatic colorectal cancer anti-EGFR treatment changed at end 2013. The set mutations to be tested extended from KRAS codons 12 and 13 NRAS exons 2, 3, 4. A European external quality assessment scheme monitored performance laboratories evaluated implementation new regulations. MATERIALS AND METHODS: 131 participating received 10 samples formalin-fixed paraffin-embedded material, including RAS (exon 4) BRAF mutations. Mock clinical data were provided three cases. Using their routine methods, determined genotypes submitted written reports. Assessors scored results according predefined evaluation criteria. RESULTS: Half participants (49.3%) had completely implemented test requirements (codons 12, 13, 59, 61, 117, 146 NRAS), 96 (73.3%) made no genotype mistakes. Correct nomenclature, Human Genome Variation Society, was used by 82 (62.6%). CONCLUSION: Although regulations effective several months, many not ready full testing in context therapy. Nevertheless, each country, there are that provide complete correct testing. External assessments can monitor stimulate improve procedures. Because this program available on website Society Pathology, clinicians refer a reliable laboratory.